Founded in 2018, Immuneel Therapeutics operates in Health Tech industry. Transitioning from research and development to clinical trials and commercialization, it secured funding in an extended Series ...
Funding stage:
Series B
Last funding:
07/06/2026
Total funding:
$37.13 Mn+
Revenue:
Investors
Employee count:
112
Last 90d
112
Last 90d
Web traffic:
2.32K
2.32K
Last 30d
Last 30d
Glassdoor Rating:
Immuneel Therapeutics: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders22
Latest Filing Date23 June 2024- Funding Events19
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Immuneel Therapeutics
As of 24 June 2024, Immuneel Therapeutics's equity is held by 21 shareholders, with the top three being Taiba Healthcare, Syngene, and Eight Roads Ventures India III LP.
Taiba Healthcare holds the largest stake in Immuneel Therapeutics at 17.0% as of 24 June 2024.
As of 24 June 2024, founders collectively hold 16.0% equity in Immuneel Therapeutics.
As of 24 June 2024, investors collectively hold 39.6% equity in Immuneel Therapeutics.
Immuneel Therapeutics's ESOP pool stands at 8.3% of total equity as of 24 June 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links